ESPR · Esperion Therapeutics, Inc.
Market Cap
$818.63M
Shares
257.43M
Esperion Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Esperion Therapeutics, Inc. (ESPR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲136.1%
$18.84M
−$56.73M
'22 Q1
22-05-03
▼53.7%
$18.84M
−$66.32M
'22 Q2
22-08-02
▲31.7%
$18.98M
−$55.12M
'22 Q3
22-11-01
▲22.2%
$18.82M
−$55.49M
'22 Q4
23-01-09
▲29.2%
$24.33M
−$61.72M
'23 Q1
23-05-09
▲36.9%
$25.79M
−$49.94M
'23 Q2
23-08-01
▲79%
$33.97M
−$41.25M
'23 Q3
23-11-07
▲71.4%
$32.25M
−$56.34M
'23 Q4
24-02-27
▲466.1%
$137.74M
$61.02M
'24 Q1
24-05-07
▲186.3%
$73.83M
−$61.92M
'24 Q2
24-08-12
▲52%
$51.63M
−$29.52M
'24 Q3
24-11-07
▲114.3%
$69.11M
−$21.32M
'24 Q4
25-01-16
▼52.8%
$65.00M
−$40.45M
'25 Q1
25-05-06
▲11.6%
$82.39M
−$12.72M
'25 Q2
25-08-05
▲69.1%
$87.31M
−$31.33M
'25 Q3
25-11-06
LATEST
▲143.7%
$168.45M
$61.83M
'25 Q4
26-03-10
Earnings call
FY25 · Q4
2026-03-10
Esperion Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
Bempedoic acid franchise
Corstasis acquisition and Enbumyst
Vision 2040 and business development
Revenue
$168.45M*
▲ 143.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Esperion Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
Generic Settlement and IP Protection
DSE Manufacturing Tech Transfer
Guideline Inclusion
Revenue
$87.31M
▲ 69.1% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Esperion Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
US commercial growth of NEXLETOL and NEXLIZET
Competitive landscape and oral non-statin entrants
Statin intolerance direct-to-consumer and digital marketing
Revenue
$82.39M
▲ 11.6% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Esperion Therapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone
ACC/AHA Guideline Inclusion
Gross Margin Trajectory
International Partnerships and Royalties
Revenue
$65.00M
▼ 52.8% YoY Diluted EPS
$-0.21
▼ 161.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-16
Esperion Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Triple Combination Pipeline
U.S. Commercial Growth
International Partnerships
Revenue
$69.11M*
▲ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Esperion Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Payer access and formulary coverage
U.S. commercial launch momentum for NEXLETOL/NEXLIZET
International growth with partners
Revenue
$51.63M
▲ 52% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Esperion Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
U.S. commercial momentum and revenue growth
International expansion (EU, Japan, Otsuka)
Expanded label and clinical data (CLEAR Outcomes)
Revenue
$73.83M
▲ 186.3% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Esperion Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
FDA label expansion for NEXLETOL/NEXLIZET
Payer access and utilization management updates
European regulatory and ex-U.S. outlook
Revenue
$137.74M
▲ 466.1% YoY Diluted EPS
$0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Esperion Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
CLEAR Outcomes data and guidelines
FDA/EMA label expansion
Quarterly revenue growth
Revenue
$32.25M*
▲ 71.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Esperion Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$33.97M
▲ 79% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Esperion Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$25.79M
▲ 36.9% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Esperion Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$24.33M
▲ 29.2% YoY Diluted EPS
$-0.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Esperion Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$18.82M*
▲ 22.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Esperion Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$18.98M
▲ 31.7% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Esperion Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$18.84M
▼ 53.7% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Esperion Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$18.84M
▲ 136.1% YoY Diluted EPS
$-0.93
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Esperion Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$15.40M*
▲ 59.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-18
Esperion Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$14.41M
▲ 275.9% YoY Diluted EPS
$-2.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Esperion Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$40.66M
▼ 80.8% YoY Diluted EPS
$-1.67
▼ 138.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Esperion Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$7.98M
▲ 333.6% YoY Diluted EPS
$-3.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Esperion Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$9.64M
▲ 881.5% YoY Diluted EPS
$-3.89
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Esperion Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$3.83M
▲ 290.7% YoY Diluted EPS
$-3.07
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Esperion Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$212.24M
▲ 21512.6% YoY Diluted EPS
$4.32
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Esperion Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$1.84M
▼ 98.7% YoY Diluted EPS
$-2.84
▼ 192.5% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Esperion Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$982,000
Diluted EPS
$-2.26
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls
Key facts
CIK
1434868
CUSIP
29664W105
13F (30d)
180 filings
177 filers
Visit website
Investor relations